Last update 21 Jun 2024
Parimifasor
Last update 21 Jun 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms LYC-30937, LYC-30937 Enteric coated, LYC-30937-EC |
Target |
Mechanism ATPase modulators(ATPase modulators), Immunomodulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Structure
Molecular FormulaC18H11Cl2F4N5O |
InChIKeyGPLAWHGEODGIAW-UHFFFAOYSA-N |
CAS Registry1796641-10-5 |
Related
5
Clinical Trials associated with ParimifasorA Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects With Moderate Chronic Plaque-Type Psoriasis
A Multicenter Open-label Extension Study to Assess the Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis
A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Assess the Efficacy and Safety of Induction Therapy With LYC-30937-EC in Subjects With Active Ulcerative Colitis
100 Clinical Results associated with Parimifasor
Login to view more data
100 Translational Medicine associated with Parimifasor
Login to view more data
100 Patents (Medical) associated with Parimifasor
Login to view more data
100 Deals associated with Parimifasor
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Plaque psoriasis | Phase 2 | US | 05 Dec 2016 | |
| Ulcerative colitis, active severe | Phase 2 | US | 01 Jul 2016 | |
| Ulcerative colitis, active severe | Phase 2 | CA | 01 Jul 2016 | |
| Ulcerative colitis, active severe | Phase 2 | CZ | 01 Jul 2016 | |
| Ulcerative colitis, active severe | Phase 2 | HU | 01 Jul 2016 | |
| Ulcerative colitis, active severe | Phase 2 | NL | 01 Jul 2016 | |
| Ulcerative colitis, active severe | Phase 2 | PL | 01 Jul 2016 | |
| Ulcerative colitis, active severe | Phase 2 | RS | 01 Jul 2016 | |
| Colitis, Ulcerative | Phase 2 | - | - | |
| Inflammatory Bowel Diseases | Phase 1 | - | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 124 | (LYC-30937-EC 25 mg PO QD) | djfeifmrjz(exsfvsttze) = fqxmfscvyf nxxumztjsi (hjjfjqemow, oggfbnjfml - rvvyfmrypd) View more | - | 02 Apr 2019 | ||
Placebo (Placebo PO QD) | djfeifmrjz(exsfvsttze) = gaehyxvjhb nxxumztjsi (hjjfjqemow, utxcgjmrjh - fxmncgzith) View more | ||||||
Phase 2 | 33 | Placebo | wjmokpdrsf(ggukxtclvp) = tphyqxnycd hbjcuzhtub (jwtuoipmzh, laukrueaea - skbbfwvuvw) View more | - | 02 Apr 2019 | ||
Phase 2 | 112 | bmnjtdcxow(nuvakblifn) = midslmalbm cpqctiqdnm (zobiuyduqi, ubfhhniukl - xuasxnflcs) View more | - | 27 Mar 2019 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free